(From left) Professors Ko Young-il and Park Chang-hee, Department of Hematology and Oncology, Seoul National University Hospital
CAR-T* cell therapy offers hope for patients with relapsed diffuse large B-cell lymphoma, but it is known that around half of these patients still have no established standard treatment and the prognosis is so poor that their life expectancy is only 6. months. In a situation where a new treatment was needed for these patients, domestic medical workers opened up their potential and expressed hope.
* Collect only T cells, which are immune cells, from the patient’s blood, inject CAR, a substance that detects cancer cells, which undergo genetic modification, and then inject it back into the lymphoma patient diffuse large B-cell that is resistant to treatment or has relapsed, age 25 or younger It is suitable for B-cell acute lymphoblastic leukemia.
At Seoul National University Hospital, Professors Ko Young-il and Park Chang-hee of the Department of Hematology-Oncology and a joint research team of the Korean Clinical Research Consortium for Lymphoma (CISL) developed an anti-cancer chemotherapy based on ‘BTK inhibitor’, a targeted anti-cancer drug used to treat low-grade lymphoma, and proved its effectiveness.
Diffuse large B-cell lymphoma is a type of aggressive lymphoma that progresses rapidly, and more than half of all lymphomas are malignant. It is treated with chemotherapy using a combination of anticancer drugs such as rituximab.4 out of 10 people do not respond to primary treatment or experience a relapse after treatmentcarry out.
Accordingly, the research team used anticancer therapy (R2A therapy) using a combination of the targeted anticancer drug ‘BTK inhibitor (acalabrutinib)’, the immunomodulating anticancer drug ‘lenalidomide’ used to treat multiple myeloma, and the C20 targeted anticancer drug ‘rituximab’. . Subsequently, a single-group phase 2 clinical trial was conducted in which this therapy was administered to 66 patients and the treatment response was monitored.
The objective response rate (ORR) of R2A therapy was 54.5%, with 36 of 66 patients showing a response to treatment. In particular, 21 patients (31.8%) achieved a complete response (CR), many of whom maintained remission without tumor progression.
According to the research team, after an average follow-up period of about 9 months, The objective response rate (ORR) was 54.5%, with more than half of all patients responding to treatment with a reduction in tumor size or complete disappearance of the tumor.showed. Especially when the tumor disappears completely. Complete response (CR) occurred in 3 out of 10 patients (31.8%). appear too The 1-year progression-free survival (PFS) rate is 33.1% of all patients, meaning that 1 in 3 patients will not have tumor progression for 1 year.He appeared.
In addition, the research team performed DNA, RNA, and protein-based biomarker analysis to identify the patient group that would be most effective with R2A therapy, and the results showed that patients with the MYD88 mutation showed or significant content activated NF-κB protein function. treatment response confirmed that
The research team found that BTK inhibitors are effective not only in low-risk lymphoma but also in low-risk lymphoma. It is also effective in treating aggressive lymphoma, and combination therapy based on this anticancer drug may be a new approach to completely cure relapsed diffuse large B-cell lymphoma.He stressed.
Professor Ko Young-il said, “Anti-cancer treatment is based on BTK inhibition Plays a pivotal role in treating patients with relapsed diffuse large B-cell lymphoma who have failed CAR-T therapy“We’ll do it,” he said. “As demonstrated by this study, If R2A therapy is combined with the recently developed dual antibody therapy and CAR-T therapy, it is expected that another treatment that increases survival rates will be developed.“It will happen,” he said.
Copyright © Kyunghyang Health.
2024-04-23 12:30:00
#combination #anticancer #drugs #discovered #relapsed #diffuse #large #Bcell #lymphoma
